The Quinone-Derived Small Molecule M5N32 Is an Effective Anti-Helicobacter pylori Agent Both In Vivo and In Vitro

Area of Science:

• Microbiology
• Drug Discovery
• Infectious Diseases

Background:

• Antibiotic resistance in Helicobacter pylori necessitates novel therapeutic agents.
• Quinone derivatives have demonstrated antitumor properties and potential for H. pylori inhibition.

Purpose of the Study:

• To evaluate the efficacy of a novel quinone compound, M5N32, against Helicobacter pylori.
• To assess M5N32's potential for treating H. pylori infections, including its activity against biofilms and in vivo efficacy.

Main Methods:

• Minimum inhibitory concentrations (MICs) determined by agar dilution.
• Biofilm inhibition assessed using SYTO9-PI staining.
• In vivo efficacy evaluated in mouse models via CFU counts and histological analysis.

Main Results:

• M5N32 demonstrated potent in vitro inhibition of planktonic and biofilm-forming H. pylori.
• No resistance to M5N32 was observed in successive bacterial generations.
• In vivo, M5N32 combined with omeprazole showed superior efficacy to standard triple therapy and was non-toxic.

Conclusions:

• M5N32 is a promising candidate for developing new anti-H. pylori therapies.
• Its effectiveness against biofilms and lack of resistance development are significant advantages.
• M5N32 offers a potential new treatment strategy for H. pylori infections.